ANTISARSCOV2.: Development and production of anti-SARS-CoV-2 antibodies intended for the investigation of COVID19 (Q2867184): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
(Removed claim: co-financing rate (P837): 76.0 percent, Removing co-finance rate from projects in portugal) |
||||||
| Property / co-financing rate | |||||||
| |||||||
| Property / co-financing rate: 76.0 percent / rank | |||||||
Revision as of 10:29, 13 September 2021
Project Q2867184 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | ANTISARSCOV2.: Development and production of anti-SARS-CoV-2 antibodies intended for the investigation of COVID19 |
Project Q2867184 in Portugal |
Statements
329,906.98 Euro
0 references
1 June 2020
0 references
31 December 2020
0 references
SICGEN - INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA LDA
0 references
40°1'45.98"N, 8°23'24.86"W
0 references
A SICGEN é uma empresa especializada na produção de anticorpos. Tem em curso projetos relacionados com pandemia atual, que envolvem a produção de anticorpos que podem ser usados em investigação, na produção de kits por laboratórios e por empresas de biotecnologia para auxiliar a combate à Covid-19. (Portuguese)
0 references
SICGEN is a company specialised in the production of antibodies. It has ongoing projects related to the current pandemic, involving the production of antibodies that can be used in research, in the production of kits by laboratories and biotechnology companies to assist in the fight against Covid-19. (English)
7 July 2021
0 references
Penela
0 references
Identifiers
CENTRO-01-02B7-FEDER-069378
0 references